Human papillomavirus vaccination: evidence base for efficacy and safety

The article provides a literature review on the prevention of cervical cancer by human papillomavirus (HPV) vaccination. Currently, 3 vaccines are available: the 4-valent vaccine against HPV types 6, 11, 16 and 18, the 9-valent vaccine against HPV types 6, 11, 16, 18, 31, 33, 45, 52, 58 and the biva...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yuliya E. Dobrokhotova, Ekaterina I. Borovkova
Formato:	article
Lenguaje:	RU
Publicado:	IP Berlin A.V. 2021
Materias:	human papillomavirus vaccination cervical cancer Gynecology and obstetrics RG1-991
Acceso en línea:	https://doaj.org/article/d3cd0860d5a44aaea2675f7a907386d8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d3cd0860d5a44aaea2675f7a907386d8
record_format	dspace
spelling	oai:doaj.org-article:d3cd0860d5a44aaea2675f7a907386d82021-12-02T19:22:24ZHuman papillomavirus vaccination: evidence base for efficacy and safety2079-56962079-583110.26442/20795696.2021.2.200742https://doaj.org/article/d3cd0860d5a44aaea2675f7a907386d82021-05-01T00:00:00Zhttps://gynecology.orscience.ru/2079-5831/article/viewFile/71011/51868https://doaj.org/toc/2079-5696https://doaj.org/toc/2079-5831The article provides a literature review on the prevention of cervical cancer by human papillomavirus (HPV) vaccination. Currently, 3 vaccines are available: the 4-valent vaccine against HPV types 6, 11, 16 and 18, the 9-valent vaccine against HPV types 6, 11, 16, 18, 31, 33, 45, 52, 58 and the bivalent vaccine against HPV types 16 and 18. Vaccination provides protection for women and men against infection with HPV and further development of HPV-associated diseases. Following immunization, seroconversion develops in 93-100% of women and in 99-100% of men and is effective in preventing incident and persistent HPV infection as well as cervical intraepithelial neoplasia. HPV immunization is ineffective in treating an existing HPV infection, genital warts, or anogenital intraepithelial neoplasia. HPV vaccination status does not affect recommendations for cervical cancer screening.Yuliya E. DobrokhotovaEkaterina I. BorovkovaIP Berlin A.V. articlehuman papillomavirusvaccinationcervical cancerGynecology and obstetricsRG1-991RUГинекология, Vol 23, Iss 2, Pp 125-130 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	human papillomavirus vaccination cervical cancer Gynecology and obstetrics RG1-991
spellingShingle	human papillomavirus vaccination cervical cancer Gynecology and obstetrics RG1-991 Yuliya E. Dobrokhotova Ekaterina I. Borovkova Human papillomavirus vaccination: evidence base for efficacy and safety
description	The article provides a literature review on the prevention of cervical cancer by human papillomavirus (HPV) vaccination. Currently, 3 vaccines are available: the 4-valent vaccine against HPV types 6, 11, 16 and 18, the 9-valent vaccine against HPV types 6, 11, 16, 18, 31, 33, 45, 52, 58 and the bivalent vaccine against HPV types 16 and 18. Vaccination provides protection for women and men against infection with HPV and further development of HPV-associated diseases. Following immunization, seroconversion develops in 93-100% of women and in 99-100% of men and is effective in preventing incident and persistent HPV infection as well as cervical intraepithelial neoplasia. HPV immunization is ineffective in treating an existing HPV infection, genital warts, or anogenital intraepithelial neoplasia. HPV vaccination status does not affect recommendations for cervical cancer screening.
format	article
author	Yuliya E. Dobrokhotova Ekaterina I. Borovkova
author_facet	Yuliya E. Dobrokhotova Ekaterina I. Borovkova
author_sort	Yuliya E. Dobrokhotova
title	Human papillomavirus vaccination: evidence base for efficacy and safety
title_short	Human papillomavirus vaccination: evidence base for efficacy and safety
title_full	Human papillomavirus vaccination: evidence base for efficacy and safety
title_fullStr	Human papillomavirus vaccination: evidence base for efficacy and safety
title_full_unstemmed	Human papillomavirus vaccination: evidence base for efficacy and safety
title_sort	human papillomavirus vaccination: evidence base for efficacy and safety
publisher	IP Berlin A.V.
publishDate	2021
url	https://doaj.org/article/d3cd0860d5a44aaea2675f7a907386d8
work_keys_str_mv	AT yuliyaedobrokhotova humanpapillomavirusvaccinationevidencebaseforefficacyandsafety AT ekaterinaiborovkova humanpapillomavirusvaccinationevidencebaseforefficacyandsafety
_version_	1718376765658759168

Human papillomavirus vaccination: evidence base for efficacy and safety

Ejemplares similares